吡格列酮对初发2型糖尿病患者脂联素、炎性因子和胰岛素抵抗的影响

目的：探讨吡格列酮对初发2型糖尿病患者脂联素、炎性因子水平及胰岛素抵抗的影响。方法：将109例初发2型糖尿病患者随机分为两组,观察组53例,对照组56例,其中对照组采取常规对症治疗,观察组在此基础上加用吡格列酮,两组均治疗12周,于治疗前后分别检测血清脂联素、肿瘤坏死因子（TNF-α）、血清高敏C反应蛋白（hs-CRP）、白介素-6（IL-6）水平,计算胰岛素抵抗指数（HOMA-IR）。结果：观察组治疗后FBG、2hPG、HbAlc和HOMA-IR指数均较治疗前和对照组治疗后低,差异具有统计学意义（P〈0.05）;观察组治疗后脂联素水平较治疗前和对照组治疗后明显增加,差异具有统计学意义（P〈0.05）;观察组治疗后血清炎性因子hs-CRP、TNF-α和IL-6较治疗前和对照组治疗后明显减少,差异具有统计学意义（P〈0.05）。结论：吡格列酮用于初发2型糖尿病的疗效显著,可增加脂联素的表达,降低机体炎症状态,并增加胰岛素敏感性,具有较好的临床应用价值。

Effect of pioglitazone on adiponectin,inflammatory factors and insulin resistance of primary type 2 diabetes

Objective： To investigate the effecd of pioglitazone on adiponectin, inflammatory factors and insulin resistance of early onset type 2 diabetes. Methods： A total of 109 patients with primary type 2 diabetes were randomly divided into two groups with 53 cases in observation group and 56 cases in control group. Both groups were given conventional symptomatic treatment, but the observation group was given extra pioglitazone. Both the two groups were treated for 12 weeks. The levels of serum adiponectin, tumor necrosis factor alpha （TNF-α）, serum high sensitivity C reactive protein （hs-CRP）, interleukin-6 （IL-6） level and calculate the insulin resistance index （HOMA-IR） respectively were tested before and after the treatment. Resuits： After treatment, FBG,2 hPG, HbAlc and HOMA-IR indexes of the observation group were decreased significantly than that before treatment and that that of the control group （P〈0.05）. After treatment, the adiponectin level of observation group was increased significantly compared with those before treatment and the control group （P〈0.05）. Serum inflammatory factor hs-CRP, TNF- α and IL-6 of the observation group after treatment were significantly lower than that before treatment and the control group （P〈0.05）.Conclusion： Pioglitazone has significant therapeutic effecst on early type 2 diabetes, it can increase the expression of adiponectin, reduce in{lammation, and increase insulin sensitivity, with good clinical application value.